August 21, 2020 10:33 AM EDT
Financing
China

Lil­ly Asia Ven­tures leads As­traZeneca spin­out's $100M push in­to Chi­na's grow­ing R&D hub in Wuxi

Amber Tong

Three years af­ter launch­ing with three pre­clin­i­cal as­sets from As­traZeneca’s R&D cen­ter in Shang­hai and $132.5 mil­lion in cash, Dizal Phar­ma has drawn mar­quee new …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

A service from the Financial Times